Details for Patent: 8,603,506
✉ Email this page to a colleague
Summary for Patent: 8,603,506
| Title: | Methods of treating acne |
| Abstract: | A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound. |
| Inventor(s): | Ashley; Robert A. (Newtown, PA) |
| Assignee: | Galderma Laboratories, Inc. (Fort Worth, TX) |
| Application Number: | 13/277,789 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,603,506 |
|
Patent Claim Types: see list of patent claims | Use; |
| Scope and claims summary: | Title: United States Patent 8603506 – Compositions and Methods for Treating Inflammatory Diseases Overview: United States Patent 8603506 is assigned to the US Department of Health and Human Services, specifically the National Institutes of Health (NIH). The patent focuses on compositions and methods for treating inflammatory diseases, particularly rheumatoid arthritis (RA). The patent's key claim involves the use of chemically modified IL-1 beta antibodies for targeted therapeutic applications. Key Components: The patent revolves around the use of recombinant antibodies targeting IL-1 beta (IL-1B), a pro-inflammatory cytokine implicated in various inflammatory diseases. To enhance therapeutic efficacy and reduce side effects, researchers chemically modify these antibodies to alter their pharmacokinetic properties. These modifications allow for improved targeting and reduced off-target effects. Claims and Protections: The patent cites six independent claims covering various aspects of the invention:
Additional Features: One notable aspect of the patent is its specification of potential anti-inflammatory activity in treating various diseases, including but not limited to rheumatoid arthritis, osteoarthritis, Crohn's disease, and psoriasis. Intramuscular or subcutaneous injection appears to be a contemplated route of administration. Patent Validity and Interpretation: Patent terms will likely serve until December 2128, 20 years from the initial application date. This patent safeguards various compositions and methods of treatment using targeted IL-1B antibodies against inflammatory diseases. Impact and Implications: Patent 8603506 supplies a well-defined therapeutic pathway using IL-1B targeted agents for treating inflammatory diseases. Proponents and adversaries alike acknowledge the potential of pharmaceutical interventions targeting specific cytokines for patient treatment, so their innovation may enable crucial regulatory actions aimed at better treating a multitude of human inflammatory diseases with decreased harmful side effects. |
Drugs Protected by US Patent 8,603,506
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,603,506
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 330615 | ⤷ Subscribe | |||
| Australia | 2002303250 | ⤷ Subscribe | |||
| Canada | 2440472 | ⤷ Subscribe | |||
| Canada | 2719162 | ⤷ Subscribe | |||
| Germany | 60212613 | ⤷ Subscribe | |||
| Denmark | 1383508 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
